Cargando…
Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
Omalizumab (Xolair) was approved by the U.S. Food and Drug Administration (FDA) on June 20, 2003, for subcutaneous (SC) treatment of adults and adolescents (aged 12 years and older) (a) who have moderate or severe persistent asthma, (b) who have a positive skin test or in vitro reactivity to a peren...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437644/ https://www.ncbi.nlm.nih.gov/pubmed/16300422 http://dx.doi.org/10.18553/jmcp.2005.11.9.774 |